Negative / Null Result ReportOpen accessMedicine· cited by 21

Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS

Yue Yang; Dominic B. Rowe; Heather McCann; Claire E. Shepherd; Jillian J. Kril; Matthew C. Kiernan; Glenda M. Halliday; Rachel H. Tan · 2023 · Neuropathology and Applied Neurobiology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

AIMS: Although the orally available brain-penetrant copper compound CuATSM has demonstrated promising effects in SOD1-linked mouse models, the impact of CuATSM on disease pathology in patients with amyotrophic lateral sclerosis (ALS) remains unknown. METHODS: The present study set out to address this deficit by performing the first pilot comparative analysis of ALS pathology in patients that had been administered CuATSM and riluzole [N = 6 cases composed of ALS-TDP (n = 5) and ALS-SOD1 (n = 1)] versus riluzole only [N = 6 cases composed of ALS-TDP (n = 4) and ALS-SOD1 (n = 2)]. RESULTS: Our re

Abstract by Yue Yang; Dominic B. Rowe; Heather McCann; Claire E. Shepherd; Jillian J. Kril; Matthew C. Kiernan; Glenda M. Halliday; Rachel H. Tan, Neuropathology and Applied Neurobiology (2023) — licensed CC BY 4.0.

Read the full paper (open access)